New Vernon Capital Holdings Ii LLC Protagonist Therapeutics, Inc Transaction History
New Vernon Capital Holdings Ii LLC
- $208 Billion
- Q2 2025
A detailed history of New Vernon Capital Holdings Ii LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, New Vernon Capital Holdings Ii LLC holds 7,198 shares of PTGX stock, worth $392,506. This represents 0.19% of its overall portfolio holdings.
Number of Shares
7,198
Previous 348,095
97.93%
Holding current value
$392,506
Previous $7.2 Million
5426.99%
% of portfolio
0.19%
Previous 0.16%
Shares
3 transactions
Others Institutions Holding PTGX
# of Institutions
295Shares Held
67.4MCall Options Held
290KPut Options Held
318K-
Farallon Capital Management LLC San Francisco, CA6.17MShares$337 Million1.53% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$314 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.76MShares$314 Million4.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.36MShares$238 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.25MShares$177 Million6.36% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.68B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...